



Universiteit
Leiden
The Netherlands

Pharmacogenetics of sunitinib in metastatic renal cell carcinoma

Diekstra, M.H.M.; Diekstra M.H.M.

Citation

Diekstra, M. H. M. (2017, September 13). *Pharmacogenetics of sunitinib in metastatic renal cell carcinoma*. Retrieved from <https://hdl.handle.net/1887/55944>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/55944>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/55944> holds various files of this Leiden University dissertation

Author: Diekstra, Meta

Title: Pharmacogenetics of sunitinib in metastatic renal cell carcinoma

Date: 2017-09-13

Pharmacogenetics of sunitinib in metastatic renal cell carcinoma

Meta Diekstra

The research presented in this thesis was performed at the department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands. Financial support for the publication of this thesis was provided by Afdelingsfonds Klinische Farmacie & Toxicologie

The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 259939.

Cover design	Guus Gijben
Lay out	Guus Gijben
Printed by	Proefschriftmaken.nl
ISBN	978-94-92026-12-5

©2017 M.H.M. Diekstra

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval, without permission in writing from the author.

Pharmacogenetics of sunitinib

in metastatic renal cell carcinoma

Proefschrift

ter verkrijging van
de graad van Doctor aan de universiteit Leiden,
op gezag van Rector Magnificus prof mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 13 september 2017
klokke 13.45 uur

door

Mathilde Hyacintha Maria Diekstra

geboren te Nijmegen
in 1986

Promotores

Prof. dr. H.-J. Guchelaar
Prof. dr. A.J. Gelderblom

Copromotor

Dr. J.J. Swen

Leden promotiecommissie

Prof. dr. J.H. Veelken
Prof. dr. C.A.J. Knibbe
St Antonius Hospital, Nieuwegein
Prof. dr. L.A.L.M. Kiemeny
Radboud University Medical Center, Nijmegen
Prof. dr. J.A. Gietema
University of Groningen and University Medical Center Groningen

Opgedragen aan mijn ouders

“He who loves practice without theory is like the sailor who boards ship without a rudder and compass and never knows where he may be cast.”

Leonardo da Vinci, 1452-1519

CONTENTS

Chapter 1	General introduction	11
Chapter 2	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review <i>Expert Rev Mol Diagn.</i> 2016;16(5):605-618.	23
Chapter 3	Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662 <i>Clin Pharmacol Ther.</i> 2014;96(1):81-89.	65
Chapter 4	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma <i>Eur Urol.</i> 2015;68(4):621-629.	91
Chapter 5	Sunitinib-induced hypertension in <i>CYP3A4</i> rs4646437 A-allele carriers with metastatic renal cell carcinoma <i>Pharmacogenomics J.</i> 2017;17(1):42-46.	115
Chapter 6	Association of single nucleotide polymorphisms in <i>IL8</i> and <i>IL13</i> with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma <i>Eur J Clin Pharmacol.</i> 2015;71(12):1477-1484.	131

Chapter 7	Evaluation of <i>KDR</i> rs34231037 as predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma <i>Pharmacogenet Genomics</i> . 2017;27(6):227-231.	149
Chapter 8	Population modelling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics and clinical outcome in sunitinib-treated cancer patients <i>CPT Pharmacometrics Syst Pharmacol</i> . 2017, accepted for publication	161
Chapter 9	Genetic biomarkers associated with efficacy of sunitinib treatment in patients with metastatic renal cell carcinoma: preliminary results from the EuroTARGET Genome-Wide Association Study. <i>Manuscript in preparation</i>	199
Chapter 10	General discussion and future perspectives	249
Chapter 11	Summary	275
	Nederlandse samenvatting	281
	List of publications	287
	Curriculum vitae	291
	Courses and training activities	295
	Dankwoord	299